Stem Cell Reports Named Official Journal for 2026 Copenhagen Disease Modelling and Drug Screening Summit

The ISSCR has named Stem Cell Reports the official journal for its 2026 conference on stem cell-based disease modelling and drug screening in Copenhagen.

By: AXL Media

Published: Mar 28, 2026, 10:44 AM EDT

Source: Information for this report was sourced from International Society for Stem Cell Research

A Strategic Alignment in Stem Cell Science

The International Society for Stem Cell Research (ISSCR) has formally announced a significant partnership, naming Stem Cell Reports as the primary editorial platform for its high-profile spring meeting. Scheduled for late April in Copenhagen, the conference will focus on the latest breakthroughs in disease modelling and pharmaceutical screening. By elevating its official peer-reviewed journal to this status, the ISSCR seeks to bridge the gap between basic laboratory discovery and the complex requirements of clinical translation. This move ensures that the high-impact research presented during the summit will have a direct and formalized path toward global dissemination within the scientific community.

Advancing Human-Relevant Preclinical Models

Central to the Copenhagen summit is the rapidly maturing field of organoid technologies and scalable screening platforms. These advanced models are increasingly viewed as superior alternatives to traditional animal testing, offering more predictive and human-relevant data during early-stage drug development. According to the ISSCR, the integration of stem cell-derived models into preclinical research is a cornerstone of modern biotechnology. By focusing on these sophisticated systems, the conference aims to address the long-standing challenges of translational failure, where therapies that appear successful in animal trials ultimately fail to perform safely or effectively in human patients.

The Role of the Global Discovery Consortium

The themes of the 2026 conference are deeply intertwined with the ISSCR’s broader strategic initiatives, specifically its Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development. This global project is dedicated to the responsible and standardized adoption of stem cell models across the pharmaceutical industry. By aligning the journal’s editorial focus with the Consortium’s goals, the society is pushing for greater scientific rigor and transparency. This initiative ensures that as these new technologies scale, they remain grounded in a framework that prioritizes human safety and the acceleration of effective new therapeutics.